Eyeworld

FALL 2024

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/1525983

Contents of this Issue

Navigation

Page 9 of 94

SHATTERING THE STATUS QUO INTERVENTIONAL GLAUCOMA iDose TR is a long duration intracameral procedural pharmaceutical that delivers prostaglandin analog therapy for the reduction of intraocular pressure in patients with open- angle glaucoma or ocular hypertension. 1 The catalyst to advance the interventional glaucoma revolution, helping you and your patients take back control of their treatment journey. Introducing Actual size 1.8mm x 0.5mm ©2024 Glaukos Corporation. All rights reserved. iDose TR and Glaukos are registered trademarks of Glaukos Corporation. PM-US-1761 INDICATIONS AND USAGE iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). IMPORTANT SAFETY INFORMATION DOSAGE AND ADMINISTRATION For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions. CONTRAINDICATIONS iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product. WARNINGS AND PRECAUTIONS iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent. ADVERSE REACTIONS In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity. Please see full Prescribing Information. You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644. 1. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023. View full prescribing information at iDoseTRhcp.com

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - FALL 2024